https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> Tailoring adjuvant endocrine therapy for premenopausal breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32778 Wed 07 Feb 2024 16:54:46 AEDT ]]> Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29893 Tue 25 Jul 2023 12:08:41 AEST ]]> Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36613 Tue 14 Mar 2023 16:05:52 AEDT ]]> Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23759 Sat 24 Mar 2018 07:11:09 AEDT ]]>